WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013059265) A COMPOUND FOR THE TREATMENT OF HEPATITIS C
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2013/059265    International Application No.:    PCT/US2012/060537
Publication Date: 25.04.2013 International Filing Date: 17.10.2012
IPC:
C07D 487/04 (2006.01), A61K 31/55 (2006.01), A61P 31/14 (2006.01)
Applicants: BRISTOL-MYERS SQUIBB COMPANY [US/US]; P.O. Box 4000 Route 206 and ProvinceLine Road Princeton, New Jersey 08543-4000 (US)
Inventors: ZHENG, Zhizhen Barbara; (US).
D'ANDREA, Stanley; (US)
Agent: EPPERSON, James; Bristol-Myers Squibb Company P.O. Box 4000 Princeton, New Jersey 08543-4000 (US)
Priority Data:
61/549,450 20.10.2011 US
Title (EN) A COMPOUND FOR THE TREATMENT OF HEPATITIS C
(FR) COMPOSÉ DESTINÉ AU TRAITEMENT DE L'HÉPATITE C
Abstract: front page image
(EN)The present invention provides (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1- methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8- yl)carbonyl)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5- carboxamide (formula I), including pharmaceutically acceptable salts, as well as compositions and methods of using the compound. The compound has activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
(FR)La présente invention concerne le (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1- méthylcyclopropyl)sulfonyl)-1a-((3-méthyl-3,8-diazabicyclo[3.2.1]oct-8- yl)carbonyl)-1,1a,2,12b-tétrahydrocyclopropa[d]indolo[2,1-a][2]- benzazépine-5-carboxamide (formule I), y compris ses sels pharmaceutiquement acceptables, ainsi que des compositions et des procédés d'utilisation du composé. Ledit composé possède une activité contre le virus de l'hépatite C (VHC) et peut être utile dans le traitement de patients infectés par le VHC.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)